BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Aug 03, 2009
 |  BioCentury  |  Emerging Company Profile

Vivaldi: Tweaking attenuation

Approved influenza vaccines have modest efficacy in patients aged 50 years and older, which comprises one of the most at-risk segments of the population. Vivaldi Biosciences Inc. hopes its NS1 deletion technology will allow it to attenuate viruses with more control, allowing it to develop a live attenuated vaccine with greater efficacy in this population.

According to CEO Douglass Given, inactivated flu vaccines approved for patients aged 50 and up are only about 30-40% protective against illness in the population and 60% effective at preventing death. He estimates that patients 50 and over make up about 80% of the seasonal influenza market.

FluMist, from the MedImmune Inc. subsidiary of AstraZeneca plc, is the only live attenuated flu vaccine approved in the U.S., but it is approved only for patients aged 2-49.

According to Vivaldi co-founder and...

Read the full 684 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >